Qelbree Starting Dose for Teenagers (13-17 years)
The recommended starting dose of Qelbree (viloxazine extended-release) for teenagers aged 12-17 years is 200 mg once daily, taken orally in the morning. 1
Dosing Algorithm for Adolescents
Initial Dosing
- Start: 200 mg once daily (taken in the morning with or without food)
- The capsule can be swallowed whole OR opened and sprinkled on applesauce or pudding 1
Titration Schedule
- After 1 week, may increase by 200 mg increment to the maximum dose of 400 mg once daily 1
- Titration is based on clinical response and tolerability 2
- Weekly increments of 200 mg are recommended until optimal response is achieved 2
Maximum Dosing
- Maximum recommended dose: 400 mg/day for adolescents 12-17 years 1
- Do not exceed this dose, as the dose-response curve suggests doses above 400 mg may not provide additional efficacy 3
Clinical Context and Evidence
The 200 mg starting dose for adolescents is higher than the 100 mg starting dose used in younger children (6-11 years), reflecting age-appropriate pharmacokinetic considerations 1. This dosing strategy is supported by Phase 3 clinical trials demonstrating that both 200 mg and 400 mg doses produced statistically significant improvements in ADHD symptoms compared to placebo in adolescents 4.
Key efficacy findings from adolescent trials:
- Both 200 mg and 400 mg doses showed significant improvement in ADHD Rating Scale-5 Total scores (p=0.0232 and p=0.0091, respectively) 4
- Clinical Global Impression-Improvement scores were significantly better at both doses (p=0.0042 and p=0.0003) 4
- The dose-response curve is bell-shaped, with optimal efficacy around 200-400 mg, suggesting higher doses offer no additional benefit 3
Important Safety Considerations
Monitoring Requirements
Before initiating treatment, assess:
- Suicidality risk - FDA black box warning for increased suicidal thoughts and behaviors; close monitoring required especially in first few months 1
- Cardiovascular status - measure heart rate and blood pressure at baseline, after dose increases, and periodically during treatment 1
- Psychiatric history - screen for bipolar disorder risk, as noradrenergic agents can trigger manic episodes 1
Common Adverse Effects in Adolescents
The most frequently reported adverse events (≥5% and twice placebo rate) include 1, 4:
- Somnolence (16% vs 4% placebo)
- Headache
- Decreased appetite
- Nausea
- Fatigue (6% vs 2% placebo)
Clinical Pearl: Somnolence and fatigue are dose-related. Advise patients not to drive or operate machinery until they know how the medication affects them 1. These effects typically emerge early in treatment.
Discontinuation Rates
Only 3-5% of adolescents discontinued due to adverse events in clinical trials, indicating good overall tolerability 1, 4. The most common reasons for discontinuation were somnolence, nausea, and headache 1.
Special Dosing Situations
Severe Renal Impairment
- Start at 100 mg once daily
- Titrate in 50-100 mg weekly increments
- Maximum: 200 mg/day 1
Hepatic Impairment
No dose adjustment needed for mild to severe hepatic impairment, as exposure changes are minimal 5
Timeline for Clinical Response
Expect symptom improvement as early as Week 1-2 of treatment, with continued improvement through Weeks 4-6 3, 6. The temporal response curves show that:
- 200 mg and 400 mg doses demonstrate gradual, sustained improvement
- Effects plateau around weeks 4-6
- Lower doses (100 mg) show more rapid decline in effect 3
This supports the 200 mg starting dose for adolescents, as it provides both early response and sustained efficacy.
Drug Interactions
Critical contraindication: Do not use with MAOIs or within 14 days of MAOI discontinuation 1
Avoid concomitant use with:
- Sensitive CYP1A2 substrates (e.g., theophylline, tizanidine)
- CYP1A2 substrates with narrow therapeutic range 1
Viloxazine is a moderate CYP1A2 inhibitor and may increase levels of drugs metabolized by this pathway 1.